Phase I study of an easy-to-use intravenous formulation of liposome entrapped c-raf antisense oligonucleotide (LErafAON-ETU) [antisense oligonucleotide c-raf-1] administered on a weekly schedule in patients with advanced cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs LErafAON (Primary)
- Indications Cancer; Various toxicities
- Focus Adverse reactions
- 04 Jul 2011 Biomarkers information updated
- 13 May 2008 IND submission expected expected mid-2008.
- 01 Feb 2007 Status changed from recruiting to in progress